Zopiclone, sleep and health‐related quality of life

Authors:
  • FGF. Goldenberg
    F. Goldenberg
  • MGM. Le Gal
    M. Le Gal

Abstract
458 insomniac patients participated in a multinational, randomised, double blind, parallel groups study of zopiclone 7.5 mg versus placebo. Patients received the drug or placebo nightly for 14 days and for a further six weeks on demand. Sleep characteristics and Quality of Life measures were assessed at 14, 28 and 56 days after admission. Both groups of patients improved on these measures, but the active treatment showed significantly greater improvement compared to placebo, both after 14 days and at the end of the trial.